This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.

Inclusion Criteria:

• Age range: 14 to 65 years-old；
• Clinically diagnosed of Port-wine Stain;
• Patients receiving hemoporfin based upon the clinical judgment of the investigator;
• Written informed consent signed and agreed to receive periodic follow-up

Exclusion Criteria:

• Allergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution;
• Scar diathesis;
• Pregnancy or unwilling to adopt reliable contraceptive measures during the month after drug application;
• Be judged not suitable to participate the study by the investigators